Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis

BACKGROUND: Some people with multiple sclerosis (pwMS) are at increased risk of severe Coronavirus disease 19 (COVID-19) and should be rapidly vaccinated. However, vaccine supplies are limited, and there are concerns about side-effects, particularly with the ChAdOx1nCoV-19 (AstraZeneca) vaccine. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen-Philbey, K., Stennett, A., Begum, T., Johnson, AC., Dobson, R., Giovannoni, G., Gnanapavan, S., Marta, M., Smets, I., Turner, B.P., Baker, D., Mathews, J., Schmierer, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129799/
https://www.ncbi.nlm.nih.gov/pubmed/34049216
http://dx.doi.org/10.1016/j.msard.2021.103028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129799/
https://www.ncbi.nlm.nih.gov/pubmed/34049216
http://dx.doi.org/10.1016/j.msard.2021.103028

Ejemplares similares